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Abstract
Background: Stereotactic body radiation therapy (SBRT) has seen increasing use as a salvage strategy for selected
patients with recurrent, previously-irradiated squamous cell carcinoma of the head and neck (rSCCHN). PET-CT may
be advantageous for tumor delineation and evaluation of treatment failures in SBRT. We analyzed the patterns of
failure following SBRT for rSCCHN and assessed the impact of PET-CT treatment planning on these patterns of
failure.
Methods: We retrospectively reviewed 96 patients with rSCCHN treated with SBRT. Seven patients (7%) were
treated after surgical resection of rSCCHN and 89 patients (93%) were treated definitively. PET-CT treatment
planning was used for 45 patients whereas non-PET-CT planning was used for 51 patients. Categories of failure
were assigned by comparing recurrences on post-treatment scans to the planning target volume (PTV) from
planning scans using the deformable registration function of VelocityAI™. Failures were defined: In-field (>75%
inside PTV), Overlap (20-75% inside PTV), Marginal (<20% inside PTV but closest edge within 1cm of PTV), or
Regional/Distant (more than 1cm from PTV).
Results: Median follow-up was 7.4 months (range, 2.6–52 months). Of 96 patients, 47 (49%) developed post-SBRT
failure. Failure distribution was: In-field–12.3%, Overlap–24.6%, Marginal–36.8%, Regional/Distant–26.3%. There was a
significant improvement in overall failure-free survival (log rank p = 0.037) and combined Overlap/Marginal
failure-free survival (log rank p = 0.037) for those receiving PET-CT planning vs. non-PET-CT planning in the overall
cohort (n = 96). Analysis of the definitive SBRT subgroup (n = 89) increased the significance of these findings (overall
failure: p = 0.008, Overlap/Marginal failure: p = 0.009). There were no significant differences in age, gender, time from
prior radiation, dose, use of cetuximab with SBRT, tumor differentiation, and tumor volume between the PET-CT
and non-PET-CT groups.
Conclusions: Most failures after SBRT treatment for rSCCHN were near misses, i.e. Overlap/Marginal failures (61.4%),
suggesting an opportunity to improve outcomes with more sensitive imaging. PET-CT treatment planning showed
the lowest rate of overall and near miss failures and is beneficial for SBRT treatment planning.
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Salvage options are limited for recurrent, previously-
irradiated squamous cell carcinoma of the head and neck
(rSCCHN), resulting in an overall poor prognosis with a
reported median survival of less than one year [1]. For
rSCCHN, surgical salvage remains the gold standard but is
only possible in approximately 20% of patients [2,3]. Re-
irradiation as a salvage strategy is frequently limited by the
normal tissue tolerance of previously-irradiated head andPlanning Scan
A
B
C
Figure 1 Examples of categories of failure. Pre-treatment scans (left) are
Recurrent tumors are contoured, compared to deformed PTVs (red), and ca
failures (blue, yellow). C–Marginal failure (blue).neck structures such as the brainstem, mandible, and spinal
cord, but has resulted in a median survival of 9–14 months
[4-8]. Stereotactic body radiation therapy (SBRT) has seen
increasing use as a salvage strategy for inoperable cancers
due to its ability to deliver potent doses of radiation to focal
areas with sub-millimeter accuracy, minimizing injury to
previously-irradiated tissues and shortening treatment
courses. Studies on SBRT for rSCCHN at the University of
Pittsburgh Cancer Institute (UPCI) and other institutionsRecurrence Scan
fused to post-treatment scans demonstrating recurrence (right).
tegorized. A–In-field (blue) and regional (yellow) failure. B–Overlap
Table 1 Patient, tumor, and treatment characteristics
Characteristic
Median age (range) 67 yr (39–91 yr)
Gender:
Male 70 (73%)
Female 26 (27%)
Primary tumor stage:
Stage I 4 (4%)
Stage II 6 (6%)
Stage III 19 (20%)
Stage IV 60 (63%)
Unknown 7 (7%)
Prior definitive therapy:
Radiation only 9 (9%)
Chemo + radiation 11 (12%)
Surgery + radiation 30 (31%)
Chemo, surgery + radiation 46 (48%)
Median prior radiation to head and neck 70 Gy (36–139 Gy)
Median time from prior radiation to first recurrence 10 mo (1.4–188 mo)
Median time from prior radiation to SBRT 12 mo (2.4–179 mo)
Median SBRT dose 44 Gy (25–50 Gy)
Median tumor volume 26.3 cc (1–205 cc)
Use of cetuximab with SBRT 41 (43%)
Patients with other distant or untreated tumors 40 (42%)
Patients treated as adjuvant to surgery 7 (7%)
Sites treated with SBRT:
Oral Cavity 15 (16%)
Nasopharynx 7 (7%)
Oropharynx 13 (14%)
Hypopharynx 7 (7%)
Larynx 7 (7%)
Retropharynx 5 (5%)
Neck 19 (20%)
Base of Skull 10 (11%)
Paranasal Sinuses 5 (5%)
Other 8 (8%)
Abbreviations: SBRT = stereotactic body radiation therapy.
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tional radiotherapy but with fewer toxicities [9-12].
In patients previously treated with surgery, chemother-
apy, and/or radiation, delineation of recurrences can be
challenging. Treatment planning involves manual delinea-
tion of tumors, and can be performed on an integrated
PET-CT scan, a PET-aided CT scan, or a CT scan alone.
PET-CT has been shown in primary disease to be more
sensitive than CT, PET, or PET-aided scans [13]. Whereas
in primary SCCHN it is accepted practice to contour
regions of lymphatic drainage and sizeable margins around
the gross tumor volume (GTV), there is no current stand-
ard regarding the use of such margins for recurrent tumors
[8]. Current studies on SBRT for rSCCHN, however, have
used small or no margins to minimize toxicity [9,10,12,14].
Hence, PET-CT is ideal for delineation in SBRT, whose
sharp dose fall-off makes accurate targeting essential. There
is yet no data showing that PET-CT is better than non-
PET-CT in SBRT treatment planning, judged best by treat-
ment outcome and patterns of failure. We hypothesized
that PET-CT planning would lead to a reduction in overall
and in particular “near miss” failures, i.e. failures at the
PTV border.
The most critical question in any analysis of radiation
therapy failures is “Was the tumor missed?” When
recurrences develop close to SBRT targets (with rapid
dose fall-off outside targets), this question can be very
difficult to answer because follow-up scans are usually
done with patients in a different position from when
they were treated. To overcome this obstacle and
analyze patterns of failure, we used the deformable regis-
tration function of the VelocityAITM [Velocity Medical
Systems, Atlanta, GA] software program to compare the
location of recurrences on post-treatment scans to the
PTV from planning scans. Failures within the PTV may
imply resistant tumors or insufficient dose, whereas fail-
ures near PTV borders could represent insufficient mar-
gins or failure of imaging to detect tumor edges. Few
studies exist on patterns of failure after SBRT and the
current study is unique in the degree of accuracy we at-
tempt to achieve in using deformable registration to
identify the location of recurrences.
Methods
Study design and patient selection
A retrospective cohort study was performed drawing
upon the largest published series from the UPCI experi-
ence in treating rSCCHN with SBRT. All patients signed
a written informed consent for treatment and the study
was approved by the institutional review board. Data
were de-identified to meet the Health Insurance Portabil-
ity and Accountability guidelines. All patients had
previously-irradiated, recurrent SCCHN and were origin-
ally treated with surgery, chemotherapy, and/or externalbeam radiation for their primary malignancies. Patients
were 18 years of age or older, had a Karnofsky perform-
ance status (KPS) of 50 or greater, and received no
chemotherapy or radiation for at least one month before
entry into the study. Patients were excluded if SBRT was
part of treatment for a primary tumor or if they had not
received prior radiation therapy.
Between June 2005 and November 2009, 111 patients
with recurrent, previously-irradiated SCCHN meeting
these criteria received either CyberknifeTM or TrilogyTM
SBRT, described in our prior reports [15,16]. Fifteen
patients had no post-treatment PET-CT scans and were
Figure 2 Distribution of failure outcomes. 47 out of 96 (49%) patients receiving SBRT for rSCCHN had treatment failures in one or more
categories. Distribution of failure events was In-field–7 (123%), Overlap–14 (24.6%), Marginal–21 (36.8%), Regional/Distant–15 (26.3%).
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(42%) had distant metastases or untreated locoregional
disease and were treated palliatively. Fifty-six patients
(58%) had no other tumors and were treated with cura-
tive salvage intent. Seven patients (7%) were treated with
adjuvant SBRT after surgical resection of rSCCHN and
89 patients (93%) were treated definitively with SBRT.
All primary tumors were confirmed to be squamous cell
carcinoma on pathology reports. Biopsies of recurrent
lesions were not routinely performed if there was sufficient
clinical suspicion of recurrence of the original tumor based
on imaging, history, or physical examination.Treatment planning and delivery
Treatment plans for patients in this study were created
using an integrated PET-CT scan, a PET-aided CT (PET-
CT from a different date fused to a CT with rigid registra-
tion), or a CT-only scan. The planning CT was acquired
with 1.25–mm thick slices in the target area. Physicians
contoured the spinal cord and other critical structures on
the planning CT. The GTV was contoured by visual in-
spection and treated without a margin (GTV=PTV).
Treatment plans were developed based on tumor
geometry and nearby critical structures. All patients
received five fractions and most (89%) received 40–50
Gy. Dose limits for normal structures were selected
based on prior irradiation and the radiation oncologist’s
clinical judgment. Dose limits were: 8 Gy (1 fraction) for
spinal cord, 9 Gy for brainstem, 20 Gy for brain, 10 Gy
for retina, optic nerves, and optic chiasm, 6 Gy for lens,
20 Gy for carotid artery, and 20 Gy for esophagus and
larynx. Dose-volume histograms for at-risk structures
were used to verify these limits. Phantom dose measure-
ments were used for quality assurance. Skull or cervicalspine tracking was used to localize lesions with a 1–mm
spatial accuracy [17].
Before treatment, patients were placed on the treatment
table with an immobilization device then fitted with a per-
sonalized thermoplastic facemask secured to the headrest.
Near-real-time digital x-rays or cone-beam CT images were
obtained during treatment to establish and verify target
locations. Treatments were administered every other day.
All patients were seen one to three months after treat-
ment and received a PET-CT, CT, or MRI as part of
their follow-up.Assessment of patterns of failure
Patterns of failure were analyzed using VelocityAITM, which
uses a modified B-spline deformable registration algorithm.
Testing of this algorithm demonstrated a mean error of 1–
2 mm for noise-free images [18,19]. Treatment response
was assessed using the RECIST (Response Evaluation Cri-
teria for Solid Tumors) criteria [20]. Failure was defined as
initial disease progression or complete response/partial re-
sponse/stable disease followed later by progressive disease.
Development of regional/distant disease (defined below)
was also considered failure if the patient had no preexisting
metastases/untreated locoregional disease.
Pre-treatment planning CT scans were deformably
registered to each subsequent post-treatment scan. The
post-treatment scan acted as the template image and the
planning CT with its associated PTV and dose map was
deformed to this image. Recurrent tumors were con-
toured on post-treatment scans. Mean dose received by
recurrent tumors was recorded using the deformed dose
map. The contoured recurrence was compared to the
deformed PTV and a category of failure was assigned
based on fraction of recurrent tumor falling within the
Table 3 Cox regression analysis for time to In field/Overlap/Marginal failure (Local control)
Overall Cohort (n = 96) Definitive SBRT Subgroup (n = 89)
Univariate Multivariate Univariate Multivariate
p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI)
PET-CT Planning 0.165 0.64 (0.34, 1.20) 0.161 Not entered 0.051 0.53 (0.28, 1.003) 0.051 0.53 (0.28, 1.003)
Tumor volume (5 cc increase) 0.609 1.01 (0.97, 1.05) 0.609 Not entered 0.495 1.003 (0.98, 1.06) 0.568 Not entered
Cetuximab with SBRT 0.861 0.95 (0.51, 1.76) 0.861 Not entered 0.354 0.74 (0.40, 1.39) 0.294 Not entered
Interval from previous radiation to recurrence (3 months increase)
0.300 0.99 (0.96, 1.01) 0.297 Not entered 0.361 0.99 (0.96, 1.01) 0.440 Not entered
Table 2 Cox regression analysis for time to Overall (any) failure
Overall Cohort (n = 96) Definitive SBRT Subgroup (n = 89)
Univariate Multivariate Univariate Multivariate
p HR (95% CI) p HR (95% CI) P HR (95% CI) p HR (95% CI)
PET-CT Planning 0.042 0.53 (0.29, 0.98) 0.042 0.53 (0.29, 0.98) 0.011 0.45 (0.24, 0.83) 0.011 0.45 (0.24, 0.83)
Tumor volume (5 cc increase) 0.364 1.02 (0.98, 1.06) 0.441 Not entered 0.406 1.02 (0.98, 1.06) 0.517 Not entered
Cetuximab with SBRT 0.916 0.97 (0.54, 1.75) 0.957 Not entered 0.379 0.76 (0.42, 1.39) 0.271 Not entered
Interval from previous radiation to recurrence (3 months increase)
0.167 0.98 (0.95, 1.01) 0.188 Not entered 0.221 0.98 (0.95, 1.01) 0.283 Not entered
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the PTV.
Previous studies on patterns of failure after Intensity-
Modulated Radiation Therapy (IMRT) for primary head
and neck cancer have defined in-field recurrences as 95%
involvement within clinical target volume (CTV), border-
of-field recurrences as 20–95% involvement within CTV,
and out-of-field recurrences as below 20% involvement
within CTV [21,22]. The current study differs in that we
treated recurrent rather than primary head and neck can-
cer. There are no standard definitions for categories of
failure after re-irradiation of recurrent head and neck can-
cer. Because re-irradiation involves smaller target volumes
and minimal margins (no CTV, GTV=PTV), we used a
less stringent definition of in-field recurrence. Few local
recurrences would otherwise meet a >95% in-field in-
volvement requirement by the time they were detected.
We divided the recurrent tumors into four categories of
failure: In-field–75% or more of recurrence within PTV,Table 4 Cox regression analysis for time to Overlap/Marginal
Overall Cohort (n = 96)
Univariate Multiv
p HR (95% CI) p HR
PET-CT Planning 0.042 0.48 (0.23, 0.98) 0.042 0.4
Tumor volume (5 cc increase) 0.415 0.98 (0.92, 1.03) 0.323 No
Cetuximab with SBRT 0.304 0.70 (0.35, 1.39) 0.337 No
Interval from previous radiation to recurrence (3 months increase)
0.512 0.99 (0.96, 1.02) 0.604 No
Abbreviations: SBRT = stereotactic body radiation therapy, HR = hazard ratio for failuOverlap–20–75% of recurrence within PTV, Marginal–
20% or less of recurrence within PTV but closest edge
within 1 cm of PTV, Regional/Distant–1 cm or more from
PTV. Examples of different patterns of failure are shown
in Figure 1.
Statistical analysis
Endpoints were time to SBRT failure and overall survival.
Failure analysis endpoints included time to overall (any)
SBRT failure, time to combined In-field/Overlap/Marginal
failure (local control), and time to combined Overlap/Mar-
ginal failure (near misses). Endpoints were evaluated in
both the overall and definitive SBRT cohorts. Multivariate
and univariate Cox regressions were used to model predic-
tors of failure and survival. Variables considered in the fail-
ure analysis were use of PET-CT planning, tumor volume,
use of cetuximab, and time from prior radiation to failure.
Variables in the survival analysis included these as well as
age, In-field/Overlap/Marginal failure, prior surgery, KPS,failure (Near misses)
Definitive SBRT Subgroup (n = 89)
ariate Univariate Multivariate
(95% CI) p HR (95% CI) p HR (95% CI)
8 (0.23, 0.98) 0.012 0.40 (0.19, 0.82) 0.009 0.40 (0.19, 0.79)
t entered 0.514 0.98 (0.92, 1.04) 0.605 Not entered
t entered 0.089 0.54 (0.27, 1.10) 0.066 0.51 (0.25, 1.04)
t entered 0.596 0.99 (0.96, 1.02) 0.963 Not entered
re, CI = confidence interval.
Table 5 Rates of failure and impact of PET-CT planning vs. non-PET-CT planning on failure
Overall Cohort (n = 96) Definitive SBRT Subgroup (n = 89)
Total PET-CT Non-PET-CT p (X2)* Total PET-CT Non-PET-CT p (X2)*
Number of patients: 96 45 51 89 45 44
Failure vs. No Failure:
% No Failure (n) 51% (49) 62% (28) 41% (21) 0.044 49% (44) 62% (28) 36% (16) 0.020
% Overall (Any) Failure (n) 49% (47) 38% (17) 59% (30) 0.044 51% (45) 38% (17) 64% (28) 0.020
Type of Failure:
% In-field (n) 7% (7) 11% (5) 4% (2) 0.247 8% (7) 11% (5) 5% (2) 0.434
% Overlap (n) 15% (14) 11% (5) 18% (9) 0.401 16% (14) 11% (5) 20% (9) 0.258
% Marginal (n) 22% (21) 13% (6) 29% (15) 0.083 22% (20) 13% (6) 32% (14) 0.045
% Regional/Distant (n) 16% (15) 13% (6) 18% (9) 0.588 16% (14) 13% (6) 18% (8) 0.573
Combined Failure Categories:
% In-field/Overlap/Marginal (n) 43% (41) 33% (15) 51% (26) 0.100 45% (40) 33% (15) 57% (25) 0.034
% Overlap/Marginal (n) 36% (35) 24% (11) 47% (24) 0.033 38% (34) 24% (11) 52% (23) 0.009
Abbreviations: SBRT = stereotactic body radiation therapy, *Chi-square comparison of PET-CT vs. non-PET-CT planning.
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ables were entered into the final multivariate model if they
reached a significance of p=0.10. Kaplan-Meier curves
were used to estimate time to failure and log-rank tests
were used to compare differences between PET-CT
planned and non-PET-CT planned patients. SPSS software
package was used for statistical analyses [IBMWSPSSW Sta-
tistics software Version 19.0].Results
Patient, tumor, and treatment characteristics
Table 1 summarizes patient, tumor, and treatment char-
acteristics. Ninety-six patients with rSCCHN meeting
criteria were treated with Cyberknife™ or Trilogy™ SBRT
between June 2005 and November 2009. In this cohort,
83% of patients originally presented with stage III–IV
primary tumors, with 60% receiving prior chemotherapy,
79% receiving prior surgery, and 48% receiving both. All
patients received prior definitive radiation therapy and
many received subsequent re-irradiation for pre-SBRT
recurrences. Median prior radiation dose was 70 Gy
(range, 36–139 Gy). Median time between prior radi-
ation and recurrence was 10 months (range, 1.4–
188 months). At the time of SBRT, 40 patients (42%)
had other untreated locoregional or distant tumors and
were treated palliatively while 56 patients (58%) had no
other sites of disease and were treated with curative in-
tent. SBRT was used for positive margins after surgical
resection of rSCCHN in seven patients (7%) whereas 89
patients (93%) were treated definitively with SBRT.
Forty-five patients (47%) were planned using PET-
CT whereas 51 patients (53%) were planned using
non-PET-CT (CT-only: 33 patients, PET-aided CT:
19 patients). Median tumor volume was 26.3 cc
(range, 1–205 cc). Median radiation dose was 44 Gy(range, 25–50 Gy) in five fractions and did not differ
significantly between the palliatively and curatively
treated patients. Forty-six patients (48%) received
concurrent biologic agents or chemotherapy with
SBRT, with cetuximab being the most common agent
(41 patients). All patients completed treatment with-
out toxicity-related breaks and median follow-up was
7.4 months (range, 2.6–52 months)Failure assessment
SBRT failure outcomes are graphically represented in
Figure 2. Of 96 patients, 47 (49%) developed post-SBRT
failures. The distribution of failure events was In-
field–seven (12.3%), Overlap–14 (24.6%), Marginal–21
(36.8%), Regional/Distant–15 (26.3%). Eleven patients
developed two types of failure. Estimated median SBRT
failure-free survival was 10.2 months. Among patients
that developed post-SBRT failure, median time to failure
was 3.8 months. There was no significant difference in
prescribed dose for different categories of failure but
there was a significance difference in mean dose received
within In-field, Overlap, and Marginal failures (44.6 Gy,
37.8 Gy, and 21.2 Gy, respectively, p< 0.001).
Cox regressions are shown in Tables 2, 3, and 4 for time
to overall (any) failure, time to In-field/Overlap/Marginal
(local) failure, and time to Overlap/Marginal (near miss)
failure, respectively. On multivariate analysis of the entire
cohort (n= 96), PET-CT treatment planning was asso-
ciated with longer overall failure-free survival (p = 0.042)
and Overlap/Marginal failure-free survival (p = 0.042) than
non-PET-CT planning. Analysis of the definitive SBRT
subgroup (n= 89) showed a more significant association
between PET-CT planning and longer overall failure-free
survival (p = 0.011) and Overlap/Marginal failure-free sur-
vival (p = 0.009). PET-CT planning was also associated
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Figure 3 PET-CT planning vs. non-PET-CT planning. A,B–Overall failure-free survival (A) and Overlap/Marginal failure-free survival (B) for PET-
CT planning (green) vs. non-PET-CT planning (blue) in the overall cohort (n = 96). C,D–Overall failure-free survival (C) and Overlap/Marginal failure-
free survival (D) for PET-CT planning (green) vs. non-PET-CT planning (blue) in the definitive SBRT cohort (n = 89).
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ginal failure-free survival in the definitive SBRT subgroup
(p= 0.051). Tumor volume, use of cetuximab, and interval
from previous radiation to recurrence were not found to
be significant predictors of failure.
Impact of planning SIM type on failure
PET-CT treatment planning was found on Cox regression
to be a significant predictor of longer failure-free survival.
There were no significant differences in age, gender, time
from prior radiation to recurrence, prescribed dose, use of
cetuximab, tumor differentiation, and tumor volume be-
tween the PET-CT and non-PET-CT groups (p> 0.05). A
greater number of patients in the PET-CT group had dis-
tant metastases/untreated locoregional disease (p=0.013)but more patients in the non-PET-CT group eventually
went on to receive chemotherapy or biologic agents post-
SBRT (p=0.001).
Table 5 shows the frequencies of SBRT failure events and
chi-square comparisons. In the overall cohort (n=96),
PET-CT (vs. non-PET-CT) planning was associated with a
lower frequency of both overall (38% vs. 59%, p=0.044)
and Overlap/Marginal (24% vs. 47%, p=0.033) failure. In
the definitive SBRT subgroup (n=89), PET-CT was more
strongly associated with a lower rate of both overall (38%
vs. 64%, p=0.020) and Overlap/Marginal (24% vs. 52%,
p=0.009) failure.
On Kaplan-Meier analysis of PET-CT planning vs.
non-PET-CT planning for the overall cohort, there was
a significant improvement in time to both overall failure
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(Figure 3B, p = 0.037) in the PET-CT group. There was
no significant difference in time to In-field/Overlap/Mar-
ginal failure (p = 0.159). In the definitive SBRT subgroup,
PET-CT planning was also associated with a significant
increase in time to overall failure and time to Overlap/
Marginal failure (Figures 3C, 3D, p = 0.008 and 0.009, re-
spectively). There was a borderline significant increase in
time to In-field/Overlap/Marginal failure (p = 0.046).
Survival assessment
Median overall survival for the entire cohort was
8.2 months. Patients without (vs. patients with) distant
metastases/untreated locoregional disease had a sig-
nificantly longer median overall survival (11.5 months
vs. 7.2 months, p = 0.003). Table 6 displays Cox regres-
sions for overall survival. Significant predictors of
decreased overall survival on multivariate analysis of
the entire cohort (n = 96) were higher tumor volume
(p = 0.03), In-field/Overlap/Marginal failure (p = 0.025),
older age (p = 0.021), and presence of distant metasta-
ses/untreated locoregional disease (p = 0.016). Signifi-
cant predictors of increased survival were prior
surgery (p = 0.004) and higher KPS (p = 0.007). On
multivariate analysis of the definitive SBRT cohort
(n = 89), tumor volume (p = 0.024), age (p = 0.012), and
presence of distant metastases/untreated locoregional
disease (p = 0.037) remained significant predictors of
decreased overall survival. Prior surgery (p = 0.01) and
KPS (p = 0.028) remained significant predictors of
increased survival. PET-CT planning, use of cetuxi-
mab, and interval from prior radiation to recurrence
were not significant predictors of survival.Table 6 Cox regression analysis for overall survival
Overall Cohort (n = 96)
Univariate Multivariate
p HR (95% CI) p HR
PET-CT Planning 0.640 1.1 (0.72, 1.71) 0.708 No
Tumor volume (5 cc increase) 0.036 1.03 (1.001, 1.06) 0.030 1.04
Cetuximab with SBRT 0.192 1.36 (0.86, 2.14) 0.431 No
Interval from previous radiation to recurrence (3 month increase)
0.731 0.997 (0.97, 1.02) 0.475 No
Any In-field/Overlap/Marginal failure
0.141 1.39 (0.90, 2.15) 0.025 1.71
Age (10 year increase) 0.273 1.11 (0.93, 1.32) 0.021 1.25
Any Prior Surgery 0.007 0.50 (0.30, 0.83) 0.004 0.46
KPS (10 KPS increase) 0.010 0.80 (0.69, 0.94) 0.007 0.79
Any distant metastases or untreated locoregional disease
0.004 1.95 (1.24, 3.07) 0.016 1.80
Abbreviations: SBRT = stereotactic body radiation therapy, HR = hazard ratio for deaDiscussion
Interest in SBRT for rSCCHN has grown due to its abil-
ity to deliver high doses of radiation to focal areas with
high precision, potentially reducing toxicity and shorten-
ing treatment courses [9-12]. This study serves as the
first analysis of patterns of failure after SBRT for
rSCCHN, and thus provides crucial information for ad-
vancing the field and enhancing efficacy of this novel
targeted therapy. The availability of many bony land-
marks in the head and neck enhances accuracy of de-
formable registration and allows a detailed pattern of
failure analysis. Our failure categories were, in order of
proximity to the PTV: In-field, Overlap, Marginal, and
Regional/Distant. We found that most failures were on
or near PTV borders (Overlap/Marginal failure, 61.4%),
rather than within the PTV (In-field failure, 12.3%) or
over 1 cm from the PTV (Regional/Distant failure,
26.3%).
Whereas most prior pattern of failure analyses of radi-
ation for primary head and neck SCC showed mostly in-
field recurrences [21,22], we found a high frequency of
edge-of-field failures after SBRT for rSCCHN. Our findings
also stand in contrast to one of the few other existing stud-
ies on patterns of failure after re-irradiation of rSCCHN,
which used IMRT and 3-D conformal radiation therapy ra-
ther than SBRT. In that study, Popovtzer et al. reported a
large majority of in-field recurrences and suggested that
confining radiation targets to the GTV could reduce tox-
icity without compromising overall control [23]. However,
that study used a 5 mm margin around the GTV (vs. no
margin in our study) and a less stringent definition of in-
field recurrence (>50% of recurrence within 95% isodose
curve vs. >75% of recurrence within PTV in our study),Definitive SBRT Subgroup (n = 89)
Univariate Multivariate
(95% CI) p HR (95% CI) p HR (95% CI)
t entered 0.657 0.91 (0.58, 1.41) 0.960 Not entered
(1.006, 1.07) 0.025 1.03 (1.001, 1.06) 0.024 1.04 (1.006, 1.07)
t entered 0.700 1.10 (0.69, 1.74) 0.827 Not entered
t entered 0.845 0.997 (0.98, 1.01) 0.433 Not entered
(1.07, 2.74) 0.547 1.15 (0.74, 1.78) 0.095 1.50 (0.93, 2.43)
(1.04, 1.49) 0.128 1.15 (0.96, 1.37) 0.012 1.27 (1.05, 1.54)
(0.27, 0.78) 0.023 0.55 (0.33, 0.92) 0.010 0.49 (0.29, 0.85)
(0.66, 0.94) 0.041 0.84 (0.71, 0.99) 0.028 0.82 (0.69, 0.98)
(1.12, 2.90) 0.024 1.69 (1.07, 2.67) 0.037 1.66 (1.03, 2.69)
th, CI = confidence interval, KPS = Karnofsky performance status.
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When we applied Popovtzer et al.’s definitions to our data-
base, Overlap/Marginal failures still accounted for 53% of
failures.
Treatment of recurrent head and neck cancer differs
from primary tumors in that for recurrences, prophylac-
tic contouring of regions of lymphatic drainage and large
margins are not standard.8 With the smaller targets and
the sharp dose fall-off involved in SBRT for rSCCHN,
the potential for near misses increases and accurate de-
tection and contouring of tumor edges becomes critical.
Detection of tumor edges may be enhanced with PET-
CT treatment planning. We found PET-CT planning to
be associated with longer overall failure-free survival and
longer Overlap/Marginal failure-free survival after SBRT
for rSCCHN, suggesting an advantage in tumor control.
This association was stronger in the definitive SBRT sub-
group, which likely reflects the higher usage of CT plan-
ning in adjuvant treatments for positive surgical margins
included in the overall cohort. For time to combined In-
field/Overlap/Marginal failure, PET-CT showed no sig-
nificant benefit in the overall cohort and only a border-
line benefit in the definitive SBRT subgroup. This
suggests that PET-CT planning improves control princi-
pally through reduction of failures on the PTV edge.
Overall survival for patients without distant metastases
or untreated locoregional disease in this study was simi-
lar to prior reports on SBRT for rSCCHN [9-12]. We
found that older age, lower performance status (KPS),
presence of distant metastases/untreated locoregional
disease, higher tumor volume, and lack of prior surgery
were significant predictors of decreased overall survival.
We did not observe a significant difference in overall
survival between the PET-CT and non-PET-CT planning
groups.
A primary limitation of the current study is our inabil-
ity to detect precisely where recurrent tumors origi-
nated. Recurrent tumors are often large by the time they
are detected and if any part of the recurrence overlaps
with the PTV border, clinical judgment becomes import-
ant in defining whether the recurrence originated from
inside or outside the PTV. This may lead to subjective
categorization of failures as in-field vs. out of field and
subsequent variation in definitions of category of failure.
Other limitations include patient heterogeneity and po-
tential variability in contouring recurrent tumors.
Conclusions
This study demonstrates that most recurrences after
SBRT for rSCCHN were near misses, i.e. failures occur-
ring near the PTV border. PET-CT treatment planning
was shown to result in lower rates of failure, particularly
near miss failures, compared to non-PET-CT planning.
PET-CT appears advantageous for treatment planning inSBRT for rSCCHN, where accurate targeting of smaller
tumor volumes within previously-irradiated tissues is
critical.
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